Peptides
KLOW: what is known about the four-peptide blend
What is KLOW?
KLOW is the common name for a four-component research blend of GHK-Cu, BPC-157, TB-500, and KPV. An 80 mg vial is commonly described as 50 mg GHK-Cu plus 10 mg each of the other three, but a catalog total alone does not verify the amount, identity, sterility, or ratio of any particular lot. The peptides are mixed together; this is not one newly studied molecule. [1]
What do the studies show?
GHK-Cu has been studied for skin and tissue biology, BPC-157 largely in animals, and KPV in preclinical inflammation models. Published work involving full-length thymosin beta-4 is not automatically evidence for a TB-500 fragment. These separate results cannot be added together to establish that the KLOW blend heals wounds, reduces inflammation, improves gut disease, or speeds recovery in humans. We did not identify a controlled human trial of this exact four-peptide blend. [2,3]
Safety
Mixing experimental substances can create unknown interactions and formulation risks. FDA’s compounding review has identified inadequate human safety information for several constituent peptides, including BPC-157 and KPV. Injectable research vials should not be treated as equivalent to tested medicines. [3]
DOSE STATUS
How much?
EVIDENCE CONTEXT
Why?
The cited evidence does not establish a dose for this use or product.
There is no established effective or safe human KLOW dose. An 80 mg label states the total amount per vial, not a dose. A clinician’s educational slide deck mentions KLOW among blends and says dosing is individualized, but does not give a composition-matched amount that can be responsibly reported as an anecdotal protocol. Giving separate GLOW or ingredient amounts as a KLOW dose would conceal the fixed ratio and missing evidence. [1,4]
Sources & further reading
- Common KLOW 80 mg component description (formulation, not clinical evidence) (opens in a new tab)klowpharmacy.com
- Utmost Muscle GHK-Cu evidence review (opens in a new tab)utmostmuscle.com
- FDA, safety review of bulk substances used in compounding (opens in a new tab)www.fda.gov
- JP Saleeby, MD, Healing Peptides lecture (educator context, not a trial) (opens in a new tab)imahealth.org